The Next Era of Ownership Begins with the All New Ledger Nano™ and Ledger Wallet™
23.10.2025 14:00:00 CEST | Business Wire | Press Release
Ledger™, the world leader in digital asset security for consumers and enterprises, today unveiled a new era for Ledger, ownership, and identity. At Ledger Op3n in Paris, Ledger launched the new Ledger Nano™ Gen5, recreated and expanded Ledger Live™ as Ledger Wallet™, and introduced Ledger Multisig.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023549325/en/
As society transitions to digital identities, challenged by AI and a blurring of physical and online worlds, authenticating what's true is critical. Ledger is redefining its products to meet this future head-on, building products to enable Proof of You and Proof of Authority at scale.
Ledger’s secure devices, formerly known as hardware wallets, are now Ledger signers. This update reflects their expanded role beyond securing financial transactions, including protecting digital identity in a world accelerated by AI. Ledger signers will continue to operate as millions now know them, by securing Ledger Wallet, formerly known as Ledger Live, the trusted interface to manage your value, connect to opportunity, and shape your future—on your terms.
Leading this evolution is the all-new Ledger Nano, reinventing our iconic signer for this new era of control, free from compromise.
Ledger Nano signers, loved by millions of users over the last decade, are an affordable shield for protecting value and a sword in the battle against scams and hacks. Ledger Nano™ Gen5 is the most powerful and playful Ledger Nano we’ve ever built—designed to secure everything from assets to identity, smart contracts to tomorrow’s protocols.
Tony Fadell, iPod inventor and Ledger board member, brought in Susan Kare, the iconic artist and graphic designer responsible for the Apple Macintosh’s original iconography, to bring even more fun to Ledger Nano. Susan designed iconography for an exclusive series of Badges to personalize your Ledger Nano, available at launch. Susan and Tony have been at the forefront of making groundbreaking technology usable and enjoyable, and brought incredible experience and expertise to the Ledger Nano project.
Ledger Nano features Bluetooth® for on-the-go signing and NFC. Ledger Recovery Key, the spare key to access your assets, will be included in every box. NFC support further enables Ledger Security Key, allowing you to use FIDO2 Passkeys to protect your logins using your Ledger signer. Ledger Nano’s secure, energy-efficient E Ink® touchscreen empowers advanced security features like Clear Signing, Transaction Check, and Ledger Security Key.
“The Ledger Nano series is the most successful digital asset security device of all time, with millions sold and none ever hacked,” said Pascal Gauthier, Chairman and CEO of Ledger. “The all new Ledger Nano is built for the challenges and opportunities of today, and ready for those coming in the future. It is the new signer for everyone, available for an accessible price, with the best security and user interface on the market. The next generation of Ledger begins today.”
Your Ledger signer is the key to an ever more powerful ecosystem, via the Ledger Wallet app. Ledger Wallet is more than a simple portfolio tracker, it’s the intuitive control center for your digital value. Ledger Wallet is the most secure wallet for digital assets and provides access to the most trustworthy services for buying, swapping, earning, and more. Together, Ledger signers and Ledger Wallet redefine what digital ownership looks like—clear, secure, and fully in your control.
Ledger Wallet features an updated user experience for Buy, Sell, Earn and Swap. It’s faster and more reliable than ever, allowing you to trade with clarity and confidence. Ledger Wallet introduces significant new features: first, users can now connect their Ledger signer directly to popular dapps, such as 1inch, for seamless and secure experiences. Additionally, Ledger is integrating Noah, known as Cash-To-Stablecoin, enabling users to top up their wallet with fiat (USD or EUR) quickly without additional fees, and instantly convert to stablecoins (USDC). Noah enables effortless use of stablecoins for on-chain transactions.
“Ledger is for people who are serious about their digital wealth, and each day more and more people become serious about their digital wealth,” said Ian Rogers, Chief Experience Officer (CXO) at Ledger. “Ledger’s dedication to security and ownership hasn’t wavered in eleven years but Ledger’s products are evolving alongside crypto, faster than ever. Today the combination of Ledger Wallet on your smartphone or computer and your Ledger signer make it easy and safe to use the full range of services offered by decentralized finance. With Ledger you can buy, swap, earn, spend, connect and do more. We support 100% of the top 100 tokens and far beyond, without ever compromising on security OR ownership. By comparison, exchanges are walled gardens and using a software wallet alone is like begging to have your wealth stolen.”
Ledger Signers will also enable Proof of Authority beyond the individual. The explosive growth of digital assets in the past 12 months has been driven in large part by institutions. Ledger Enterprise is the trust layer for the digital asset economy—the platform built for leading banks, custodians, governments, foundations, and crypto-native businesses to secure and move billions with absolute confidence. Every decision is Clear Signed, verified on-device at the hardware layer, so no approval will ever keep your team up at night.
Today we announced Ledger Enterprise is becoming even more versatile. Unveiled at Ledger Op3n, Ledger Multisig turns high-stakes operations into precise, verifiable decisions. Every approval is Clear Signed on a Ledger device, so every action is seen, understood, and locked with cryptographic certainty. Designed for treasury management, smart contract governance, and multi-chain workflows, Ledger Multisig gives leaders a single, trusted point of truth for billions in motion—without slowing down a single move. This isn’t just security. It’s certainty at scale.
The all new Ledger Nano, Ledger Wallet, and Ledger Multisig were battle-tested by the Donjon, Ledger’s industry-leading team of white hat hackers, and audited by external security experts. Ledger Nano is available to order on Ledger.com and through our retail partners worldwide for $179/€179.
Ledger Nano™ is available for sales globally and pre-sale only in the U.S., subject to the FCC rules. Delivery is subject to FCC product certification approval. The FCC equipment authorization application has been filed and is expected to be approved once processing resumes after the US government shutdown.
SPECS:
Dimensions: 79.40 mm × 53.35 mm × 8.64 mm
Security: Ledger EAL 6+ certified secure element (ST33K1M5)
Screen type: E Ink®, monochrome (pure black and white), customizable always-on lock screen, capacitive touch
Screen resolution: 2.76”, 400 px (height) × 300 px (width) with 181 ppi
Weight: 46g
Connectivity: USB C, Bluetooth® 5.2, NFC (Ledger Recovery Key included in box)
ABOUT LEDGER
Celebrating its 10 year anniversary in 2024, Ledger is the world leader in Digital Asset security for consumers and enterprises. Ledger offers connected devices and platforms, with more than 8M devices sold to consumers in 165 countries and 10+ languages, 100+ financial institutions and commercial brands. Over 20% of the world’s crypto assets are secured by Ledger.
Ledger is the digital asset solution secure by design. The world’s most internationally respected offensive security team, Ledger Donjon, is relied upon as a crucial resource for securing the world of Digital Assets. With over 14 billion dollars hacked, scammed or mismanaged in 2023 alone, Ledger’s security brings peace of mind and uncompromising self-custody to its community.
Don’t buy “a hardware wallet.” Buy a LEDGER™ device.
LEDGER™, LEDGER LIVE™, LEDGER RECOVER™, LEDGER NANO™, LEDGER STAX™, and LEDGER FLEX™ are trademarks owned by Ledger SAS
Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Ledger is under license.
E Ink® is a registered trademark of E Ink Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251023549325/en/
Contacts
For media inquiries please contact ledger@150bond.com.
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom